Search Results

Align Technology, Inc. today announced it has appointed Emory Wright, executive vice president, direct fabrication manufacturing platform, effective immediately.

Checkpoint Therapeutics, Inc. today announced it has reached alignment with the Food and Drug Administration (“FDA”) on its biologics license application (“BLA”) resubmission strategy for cosibelimab.

Align Technology, Inc., a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, reported financial results for the fourth quarter and year ended December 31, 2023.

Align Technology, Inc. announced that it is planning to repurchase $100 million of Align’s common stock through open market repurchases under Align’s $1.0 billion stock repurchase program that was approved by Align’s Board of Directors in January 2023.

JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the publication of results from the ALIGN-AR Pivotal Trial in The Lancet.

Align Technology, Inc. announced that the company is scheduled to speak at the following upcoming financial conferences.

Align Technology, Inc. introduced a new SmartForce feature, attachment-free aligner activation, that helps minimize the number of attachments while maintaining predictable treatment outcomes.

Reviva Pharmaceuticals Holdings, Inc. announced today it has gained alignment with the U.S. Food and Drug Administration (FDA) on its registrational Phase 3 program for brilaroxazine in schizophrenia.

Cogent Biosciences, Inc. announced it has reached alignment with the U.S. Food and Drug Administration on the Company’s novel patient reported outcome measure, Mastocytosis Symptom Severity Daily Diary, for use in Part 2 of the registration-directed SUMMIT trial evaluating bezuclastinib in Nonadvanced Systemic Mastocytosis patients.